Opus Genetics to Present at the Guggenheim Annual Healthcare Innovation Conference
Globe Newswire•03/11/2026•07:00 ET
0
Key Highlights
- ➤Opus Genetics to participate in Guggenheim Healthcare Innovation Conference Fireside Chat November 10
- ➤Webcast will be available live and archived through Opus Genetics’ investor website
- ➤Opus Genetics pipeline includes seven AAV-based inherited retinal disease programs
- ➤OPGx-RDH12 cleared to enter the clinic
RESEARCH TRIANGLE PARK, N.C., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), announced today that management will participate in a Fireside Chat at the Guggenheim Annual Healthcare Innovation Conference on Tuesday, November 10, 2026 at 11:00 a.m. ET.
A link to the live and archived webcast may be accessed on Opus Genetics’ website under the Investors section: Events.
Get started
Create a free account to read the full story.